Rizatriptan Benzoate
Product Images NDC 76282-462

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 76282-462). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Exelan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Rizatriptan10mgcarton (Rizatriptan 10mg Carton)

Packaging label for Rizatriptan Benzoate Tablets USP, 10 mg, manufactured by Exelan Pharmaceuticals Inc. The label shows the product name, strength, dosage form, NDC number 76282-463-18, and indicates 18 unit-dose tablets distributed as 3 blister cards of 6 tablets each. It includes pharmacist dispensing instructions and storage warnings.*

FDA Label Image

Rizatriptan10mgfoil (Rizatriptan 10mg Foil)

Rizatriptan Benzoate Tablet, USP 10 mg (base) label showing six identical medication labels arranged in two rows of three. Each label includes NDC 76282-463-06, a warning to keep out of reach of children, manufacturer Exelan Pharmaceuticals Inc. in Boca Raton, FL, a barcode, and placeholders for lot number and expiration date. The labels are intended for the 10 mg strength tablet packaging.*

FDA Label Image

Rizatriptan5mgcarton (Rizatriptan 5mg Carton)

Packaging label for Rizatriptan Benzoate Tablets, USP 5 mg, manufactured by Exelan Pharmaceuticals Inc. The label states 18 unit-dose tablets, packaged as 3 blister cards of 6 tablets each. Includes NDC 76282-462-18, usage warnings, storage instructions, and a barcode. The design features a star pattern along the left edge and the Exelan Pharmaceuticals logo.*

FDA Label Image

Rizatriptan5mgfoil (Rizatriptan 5mg Foil)

Six identical labels for Rizatriptan Benzoate Tablet USP 5 mg (base), manufactured for Exelan Pharmaceuticals Inc., Boca Raton, FL. Each label includes an NDC 76282-462-06, a warning to keep out of reach of children, barcodes, placeholder lot numbers, and expiration dates, with a revision date of 05/2020.*

FDA Label Image

Rizatriptanfigure1 (Rizatriptan Fig1)

A line graph illustrating the estimated probability of response over time, comparing placebo and Rizatriptan Benzoate Tablets at 5 mg and 10 mg doses. The x-axis represents hours post-dose (0 to 2 hours), while the y-axis shows the estimated probability of response from 0% to 100%. The graph shows increasing response probabilities for both Rizatriptan doses compared to placebo within 2 hours.*

FDA Label Image

Rizatriptanfigure2 (Rizatriptan Fig2)

A line graph showing the estimated probability of medication rescue over 24 hours post-dose for Rizatriptan Benzoate tablets 5 mg and 10 mg compared to placebo. The graph illustrates response rates over time with three distinct curves representing placebo, 5 mg, and 10 mg doses.*

FDA Label Image

Rizatriptanfigure5 (Rizatriptan Fig5)

A line graph comparing the percentage response over time in hours post stage 2 dose between Rizatriptan Benzoate orally disintegrating tablets and placebo. The x-axis shows time from 0.5 to 2 hours, and the y-axis represents percent response with error bars indicating 95% confidence intervals. Rizatriptan shows a higher percent response than placebo at each time point.*

FDA Label Image

Structure (Rizatriptan Str)

Chemical structure of Rizatriptan Benzoate showing the molecular arrangement of the rizatriptan moiety and the benzoate component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.